Warning! GuruFocus detected
4 Severe warning signs
with ER4.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Emergent BioSolutions Inc
NAICS : 325412
SIC : 2834
ISIN : US29089Q1058
Share Class Description:
FRA:ER4: Ordinary SharesDescription
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 1.38 | |||||
| Debt-to-EBITDA | 17.99 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.9 | |||||
| Beneish M-Score | -3.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -14.2 | |||||
| 3-Year EBITDA Growth Rate | -56.6 | |||||
| 3-Year FCF Growth Rate | -27.6 | |||||
| 3-Year Book Growth Rate | -34.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.1 | |||||
| 9-Day RSI | 27.66 | |||||
| 14-Day RSI | 27.53 | |||||
| 3-1 Month Momentum % | -25.24 | |||||
| 6-1 Month Momentum % | -15.9 | |||||
| 12-1 Month Momentum % | 238.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 1.77 | |||||
| Cash Ratio | 0.61 | |||||
| Days Inventory | 172.96 | |||||
| Days Sales Outstanding | 50.03 | |||||
| Days Payable | 48.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 81.91 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.78 | |||||
| Operating Margin % | -8.04 | |||||
| Net Margin % | -18.8 | |||||
| FCF Margin % | 2.95 | |||||
| ROE % | -35.42 | |||||
| ROA % | -11.9 | |||||
| ROIC % | -7.65 | |||||
| 3-Year ROIIC % | 39.02 | |||||
| ROC (Joel Greenblatt) % | -11.31 | |||||
| ROCE % | -6.29 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.24 | |||||
| PS Ratio | 0.26 | |||||
| PB Ratio | 0.56 | |||||
| Price-to-Free-Cash-Flow | 8.88 | |||||
| Price-to-Operating-Cash-Flow | 5.04 | |||||
| EV-to-EBIT | -11.78 | |||||
| EV-to-Forward-EBIT | 5.27 | |||||
| EV-to-EBITDA | 22.95 | |||||
| EV-to-Revenue | 0.83 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| EV-to-FCF | 22.95 | |||||
| Price-to-GF-Value | 0.61 | |||||
| Price-to-Projected-FCF | 0.6 | |||||
| Price-to-Median-PS-Value | 0.07 | |||||
| Earnings Yield (Greenblatt) % | -8.49 | |||||
| FCF Yield % | 12.03 | |||||
| Forward Rate of Return (Yacktman) % | 49.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Emergent BioSolutions Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 935.979 | ||
| EPS (TTM) (€) | -3.54 | ||
| Beta | 2.41 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.27 | ||
| Volatility % | 219.58 | ||
| 14-Day RSI | 27.53 | ||
| 14-Day ATR (€) | 0.241608 | ||
| 20-Day SMA (€) | 5.0376 | ||
| 12-1 Month Momentum % | 238.98 | ||
| 52-Week Range (€) | 1.7155 - 13.78 | ||
| Shares Outstanding (Mil) | 54.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Emergent BioSolutions Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Emergent BioSolutions Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Emergent BioSolutions Inc Frequently Asked Questions
What is Emergent BioSolutions Inc(FRA:ER4)'s stock price today?
The current price of FRA:ER4 is €4.34. The 52 week high of FRA:ER4 is €13.78 and 52 week low is €1.72.
When is next earnings date of Emergent BioSolutions Inc(FRA:ER4)?
The next earnings date of Emergent BioSolutions Inc(FRA:ER4) is 2025-05-01 Est..
Does Emergent BioSolutions Inc(FRA:ER4) pay dividends? If so, how much?
Emergent BioSolutions Inc(FRA:ER4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers